Pfizer reported strong sales for its biosimilars portfolio, but these were eclipsed by the massive success of the company's mRNA vaccine for COVID-19.
Pfizer reported second-quarter 2021 biosimilar revenues up 88% from the comparable second quarter of 2020. These were dwarfed, however, by sales of the Pfizer-BioNTech COVID-19 vaccine.
Biosimilar sales for the second quarter of 2021 were $559 million globally, primarily fueled by the launches of bevacizumab (Zirabev), rituximab (Ruxience), and trastuzumab (Trazimera) biosimilars.
The company also reported ongoing growth in sales of its epoetin alfa biosimilar (Retacrit) in the United States. Retacrit was launched in 2018 and remains the only epoetin biosimilar in the United States.
Pfizer also reported a 19% decline in global sales of its etanercept originator product (Enbrel) owing to biosimilar competition in Europe and Japan. Enbrel does not yet face biosimilar competition in the United States.
Although growth in biosimilar sales at Pfizer has been robust over the past year, the company’s core business focus is now commercialization of its mRNA COVID-19 vaccine (BNT162b2) and regulatory interaction globally to broaden access and flexibility for use of this product.
Pfizer said it anticipates 2021 revenues of $33.5 billion for BNT162b2, which reflects 2.1 billion doses that Pfizer had contracted to deliver as of mid-July 2021. The company reported overall second quarter 2021 revenues of $19 billion, up 86% from the comparable 2020 quarter.
Without the COVID-19 vaccine, Pfizer’s revenues would have climbed just 10% overall, to $11.1 billion, the company said.
For a report on the company’s first quarter 2021 revenues, click here.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.